Development
GSK plc
GSK
$40.86
-$0.34-0.83%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 10.00B | 10.32B | 8.98B | 8.44B | 8.66B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 10.00B | 10.32B | 8.98B | 8.44B | 8.66B |
| Cost of Revenue | 3.50B | 2.84B | 2.38B | 2.32B | 3.16B |
| Gross Profit | 6.51B | 7.48B | 6.61B | 6.12B | 5.51B |
| SG&A Expenses | 3.25B | 2.80B | 2.83B | 2.52B | 2.84B |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -899.33M | -395.03M | -455.63M | -48.57M | -217.28M |
| Total Operating Expenses | 7.97B | 7.08B | 6.42B | 6.29B | 7.61B |
| Operating Income | 2.04B | 3.24B | 2.57B | 2.15B | 1.05B |
| Income Before Tax | 470.78M | 2.27B | 2.49B | 2.32B | 1.91B |
| Income Tax Expenses | -23.60M | 325.39M | 302.92M | 335.14M | 1.17M |
| Earnings from Continuing Operations | 494.38M | 1.94B | 2.18B | 1.98B | 1.91B |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -5.87M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -59.62M | -88.63M | -151.46M | -171.21M | -146.81M |
| Net Income | 434.76M | 1.85B | 2.03B | 1.81B | 1.76B |
| EBIT | 2.04B | 3.24B | 2.57B | 2.15B | 1.05B |
| EBITDA | 2.81B | 3.97B | 3.13B | 2.93B | 1.68B |
| EPS Basic | 0.11 | 0.46 | 0.50 | 0.45 | 0.44 |
| Normalized Basic EPS | 0.26 | 0.45 | 0.33 | 0.26 | 0.08 |
| EPS Diluted | 0.11 | 0.45 | 0.50 | 0.44 | 0.43 |
| Normalized Diluted EPS | 0.26 | 0.44 | 0.33 | 0.25 | 0.08 |
| Average Basic Shares Outstanding | 4.06B | 4.06B | 4.05B | 4.04B | 4.03B |
| Average Diluted Shares Outstanding | 4.12B | 4.11B | 4.09B | 4.09B | 4.09B |
| Dividend Per Share | 0.20 | 0.18 | 0.18 | 0.17 | 0.16 |
| Payout Ratio | 162.29% | 38.73% | 34.30% | 37.25% | 43.75% |